Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 198-204

  Park, Jong Y ^a   Kim, Donghwa ^a   Yang, Mihi ^b   Park, Hyun Y ^a   Lee, Sang Haak ^c   Rincon, Maria ^a   Kreahling, Jenny ^a   Plass, Christoph ^d,e   Smiraglia, Dominic J ^d,f   Tockman, Melvyn S ^a   Kim, Seung Joon ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Sookmyung Women's University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d OHIO STATE UNIVERSITY   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

DNA methylation; Gene silencing; Lung cancer; Restriction landmark genomic scanning; SLC5A8; Tumor suppressor gene

Indexed keywords

AZACITIDINE; BISULFITE; GENOMIC DNA; RNA; SOLUTE CARRIER FAMILY 5 MEMBER 8 PROTEIN; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCUS; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; PROMOTER REGIONS, GENETIC; SUPPRESSION, GENETIC;

EID: 84873208308     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.019     Document Type: Article

References (42)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
3. Heller G., Zielinski C.C., Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010, 29:95-107.
4. Dong S.M., Lee E.J., Jeon E.S., Park C.K., Kim K.M. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005, 18:170-178.
5. Srinivas S.R., Gopal E., Zhuang L., Itagaki S., Martin P.M., Fei Y.J., et al. Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). Biochem J 2005, 392:655-664.
6. Gopal E., Miyauchi S., Martin P.M., Ananth S., Roon P., Smith S.B., et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res 2007, 24:575-584.
7. +-coupled transporter for active uptake of l-lactate and ketone bodies in the brain. J Neurochem 2006, 98:279-288.
8. Miyauchi S., Gopal E., Babu E., Srinivas S.R., Kubo Y., Umapathy N.S., et al. Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Biochim Biophys Acta 2010, 1798:1164-1171.
9. Thangaraju M., Cresci G., Itagaki S., Mellinger J., Browning D.D., Berger F.G., et al. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg 2008, 12:1773-1781. [discussion 81-2].
10. Gupta N., Martin P.M., Prasad P.D., Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 2006, 78:2419-2425.
11. Thangaraju M., Gopal E., Martin P.M., Ananth S., Smith S.B., Prasad P.D., et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 2006, 66:11560-11564.
12. Ganapathy V., Thangaraju M., Gopal E., Martin P.M., Itagaki S., Miyauchi S., et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 2008, 10:193-199.
13. Thangaraju M., Karunakaran S.K., Itagaki S., Gopal E., Elangovan S., Prasad P.D., et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 2009, 115:4655-4666.
14. Singh N., Thangaraju M., Prasad P.D., Martin P.M., Lambert N.A., Boettger T., et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem 2010, 285:27601-27608.
15. Li H., Myeroff L., Smiraglia D., Romero M.F., Pretlow T.P., Kasturi L., et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 2003, 100:8412-8417.
16. Ueno M., Toyota M., Akino K., Suzuki H., Kusano M., Satoh A., et al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 2004, 25:134-140.
17. Ganapathy V., Gopal E., Miyauchi S., Prasad P.D. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans 2005, 33:237-240.
18. Hong C., Maunakea A., Jun P., Bollen A.W., Hodgson J.G., Goldenberg D.D., et al. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res 2005, 65:3617-3623.
19. Porra V., Ferraro-Peyret C., Durand C., Selmi-Ruby S., Giroud H., Berger-Dutrieux N., et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005, 90:3028-3035.
20. Hu S., Liu D., Tufano R.P., Carson K.A., Rosenbaum E., Cohen Y., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006, 119:2322-2329.
21. Paroder V., Spencer S.R., Paroder M., Arango D., Schwartz S., Mariadason J.M., et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci USA 2006, 103:7270-7275.
22. Park J.Y., Zheng W., Kim D., Cheng J.Q., Kumar N., Ahmad N., et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev 2007, 31:359-365.
23. Bennett K.L., Karpenko M., Lin M.T., Claus R., Arab K., Dyckhoff G., et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 2008, 68:4494-4499.
24. Park J.Y., Helm J.F., Zheng W., Ly Q.P., Hodul P.J., Centeno B.A., et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas 2008, 36:e32-e39.
25. Whitman S.P., Hackanson B., Liyanarachchi S., Liu S., Rush L.J., Maharry K., et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008, 112:2013-2016.
26. Kerr C.A., Dunne R., Hines B.M., Zucker M., Cosgrove L., Ruszkiewicz A., et al. Measuring the combinatorial expression of solute transporters and metalloproteinases transcripts in colorectal cancer. BMC Res Notes 2009, 2:164.
27. Lin H.Y., Park H.Y., Radlein S., Mahajan N.P., Sellers T.A., Zachariah B., et al. Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology 2011, 78. 971.e1-9.
28. Park J., Brena R.M., Gruidl M., Zhou J., Huang T., Plass C., et al. CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomark 2005, 1:193-200.
29. Costello J.F., Hong C., Plass C., Smiraglia D.J. Restriction landmark genomic scanning: analysis of CpG islands in genomes by 2D gel electrophoresis. Methods Mol Biol 2009, 507:131-148.
30. Okuizumi H., Takamiya T., Okazaki Y., Hayashizaki Y. Restriction landmark genome scanning. Methods Mol Biol 2011, 791:101-112.
31. Warnecke P.M., Stirzaker C., Song J., Grunau C., Melki J.R., Clark S.J. Identification and resolution of artifacts in bisulfite sequencing. Methods 2002, 27:101-107.
32. Okino S.T., Pookot D., Li L.C., Zhao H., Urakami S., Shiina H., et al. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res 2006, 66:7420-7428.
33. Plass C., Weichenhan D., Catanese J., Costello J.F., Yu F., Yu L., et al. An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. DNA Res 1997, 4:253-255.
34. Smiraglia D.J., Fruhwald M.C., Costello J.F., McCormick S.P., Dai Z., Peltomaki P., et al. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics 1999, 58:254-262.
35. Smiraglia D.J., Kazhiyur-Mannar R., Oakes C.C., Wu Y.Z., Liang P., Ansari T., et al. Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics 2007, 8:446.
36. Geng X., Wang F., Zhang L., Zhang W.M. Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori 2009, 95:488-494.
37. Ogiwara H., Kohno T., Nakanishi H., Nagayama K., Sato M., Yokota J. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene 2008, 27:4788-4797.
38. Tseng R.C., Chang J.W., Hsien F.J., Chang Y.H., Hsiao C.F., Chen J.T., et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 2005, 117:241-247.
39. Ho W.L., Chang J.W., Tseng R.C., Chen J.T., Chen C.Y., Jou Y.S., et al. Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev 2002, 26:343-349.
40. Brim H., Kumar K., Nazarian J., Hathout Y., Jafarian A., Lee E., et al. SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas. PLoS One 2011, 6:e20216.
41. Schagdarsurengin U., Gimm O., Dralle H., Hoang-Vu C., Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 2006, 16:633-642.
42. Babu E., Ramachandran S., CoothanKandaswamy V., Elangovan S., Prasad P.D., Ganapathy V., et al. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene 2011, 30:4026-4037.